Welcome to the 2018



Top 3 by 2023


State of the BioHealth Capital Region's EcoSystem




Rich Bendis
President & CEO, BioHealth Innovation Inc.



BioHealth Capital Region Forum Growth







BHCR Support Organizations





Richard A. Bendis
President /CEO

BHI sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth





George Davis, CEO

"TEDCO provides framework of knowledge, funding, and networking to support an innovation eco-system that nurtures researchers, entrepreneurs, start-ups, and early stage companies engaged in bringing innovation ideas to market."





Tami Howie, CEO

"We are a collaborative community that is actively engaged in building strong technology and life science industries by supporting the efforts of our individual members."





Jeffrey M. Gallagher CEO

"We fuel the network of leaders that drive bioscience to eradicate disease, save lives, and feed the world.....one innovation at a time."

APRIL 23, 2018




Darwin of Collaboration


"It is a long history of humankind (and animal kind, too) those who learned to collaborate and improvise most effectively have prevailed."


- Charles

Darwin












BHCR Innovation & Commercialization Network



APRIL 23, 2018



Goals of the Forum

The region's leaders will:

- create new connections, leverage strengths, seize opportunities
- share developments of the year across the region
- continue evaluating region's strengths, weaknesses, opportunities, threats
- further develop vision and identity for region

BioHealth Capital Region Initiative leaders will:

- report progress against goals from last year's conference
- Set new goals for coming year, informed by Forum participants





Top 10 U.S. Biopharma Clusters

Ranking Based on Five Criteria:

- 1. NIH Funding
- 2. Venture Capital Funding
- 3. Patents
- 4. Lab Space
- 5. Jobs

2017

- 1. Boston / Cambridge, MA
- 2. San Francisco Bay Area
- 3. New York-New Jersey
- 4. San Diego
- 5. Maryland / Virginia / DC Metro
- 6. Greater Philadelphia
- 7. Seattle
- 8. Raleigh-Durham, NC (inc. Research Triangle Park, NC)
- 9. Los Angeles / Orange County
- 10. Chicagoland



BHCR News Stories



MedImmune spins out Viela Bio....

"Viela Bio Spins Out of MedImmune; Launches with Up to \$250 Million Series A Financing from Investor Consortium Led by Boyu Capital, 6 Dimensions Capital, and Hillhouse Capital"



Deerfield \$40 million investment in Dracen....

"Health care-focused Deerfield Management leads Baltimore biotech's \$40M round"

THE BALTIMORE SUN

Emergent major contract or opens innovation Center in Baltimore....

"Emergent BioSolutions opens expanded East Baltimore vaccine plant"



Paragon Biosciences expansion....

"Paragon Bioservices Announces New Commercial Manufacturing Facility Expansion"



Supernus expansion

"Supernus To Expand, Will Move From Rockville To Gaithersburg"



Precision medicine raises \$275 million....

"Precision Medicine Group Raises \$275M to Support Biomarker-Guided Drug Development"




Sucampo sale

"Sucampo Pharmaceuticals closes on its \$1.2B sale to a U.K. company"

APRIL 23, 2018



Venture Investment in Healthcare in the BHCR



Strong Angel activity

Active ecosystem of independent angels, angel groups, and angel syndicates that invest in an average of 45 deals per year



Consistent Series A activity

Numerous regional and national funders are active in the BHCR for Series A and late-stage venture capital deals



Growing Gap at Seed Stage Deals

With an average 15 seed deals per year, strong startups don't receive funding to conduct necessary experiments for a Series A investment

APRIL 23, 2018

18 Advancing Science

BIOHEALTH & CAPITAL & FORUM

#BHCRForum18

Data gathered from Pitchbook 2018

Recent Venture Capital Company Successes in BHCR





Raised \$14M to date



Johns Hopkins spin-out Raised \$40M to date



Johns Hopkins spin-out Raised \$49M to date



Johns Hopkins spin-out Raised \$14M to date



Johns Hopkins spin-out Raised \$28.2M to date



Technology from Yale Raised \$67M to date



Johns Hopkins spin-out Raised \$99.3M to date



Raised \$275M to date



Raised \$10M to date



Johns Hopkins spin-out Raised \$6.6M to date



Pfizer spin-out Raised \$103M to date



MedImmune/AstraZeneca spin-out Raised \$250M to date

APRIL 23, 2018

#BHCRForum18



Data gathered from Pitchbook 2018

Additional BHCR Successes







medicines for all





Hemoshear and **Takeda Pharmaceutical Company** announce a multimillion dollar partnership to discover and develop novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH)

Landos Biopharma Raises \$10 Million in Series A Financing

Medicines for All Institute created with additional \$25M Gates Foundation Grant to VCU School of Engineering to increase global access to life saving medicines.

Ceres Nanosciences raises \$7 Million in Series A Funding; receives DARPA award to adapt Nanotrap® and, with GMU, Tasso & USAMRIID receives \$4.25M from DTRA

ivWatch raises \$14.8M; receives FDA 510 (k) clearance on device advancing the safety of IV therapy for pediatric patients



APRIL 23, 2018



BioHealth Capital Regions Serial Entrepreneurs



Mark P. Clein

- Precision for Medicine. Inc.
- United BioSource Corporation
- Infoscriber Corporation
- U.S. BioServices, Inc.



Rachel King

- GlycoMimetics
- NEA
- · Genetic Therapy, Inc.



Michael Richman

- NextCure
- Amplimmune



James S. Gammie. MD

- · Correx, Inc.
- Harpoon Medical, Inc.



Ethan D. Leder

- · Precision for Medicine, Inc.
- United BioSource Corporation
- · U.S. BioServices, Inc.



Martine A. Rothblatt Ph.D., J.D.

- United Therapeutics Corporation
- GeoStar
- · SiriusXM Satellite Radio



Murat V. Kalayoglu

- Cartesian Therapeutics
- Topokine Therapeutics
- HealthHonors Corporation



Wendy Perrow

- AsclepiX Therapeutics
- · Alba Therapeutics Corporation



Steve Turner

- · Protea Biosciences Group, Inc.
- · Clinomics BioSciences Inc.
- · Quorum Sciences



STATE OF VENTURE-BACKED STARTUPS IN HEALTHCARE

BHCR has Several Good Exits









M&As since 2012

\$10.2 billion

Total M&A value







IPOs since 2012

\$28.3 billion

Total IPO value







University Progress

- USM and JHU have had over 52 life science startups in last 18 months, many receiving venture capital, 4.0 billion in research expenditures, 104 licenses executed, \$60 million in license income, 1208 patent applications filed 258 Patent's issued
- USM has created a new \$25 million momentum venture fund
- New Bluefield Innovations Fund, operated by Deerfield Management to capitalize \$75 million fund to support JHU startups
- UVA entered into partnership with Inova to create a Northern Virginia research and education campus













Regional Initiatives

- Many independent regional initiatives highlighted in this Forum and for first time communication with each other
- Maryland Life Science Advisory Board implementing recommendations for Governor Hogan
- Greater Washington Partnership launched as well as Global Cities Export initiative
- MTC Merger Completed
- MCEDC and WorkSource Montgomery two new private public partnerships operational


















Investment Conference October 9 + 10, 2018



BHCR Next Steps

- Market the Brand
- Increase Collaboration
- Leverage our Extensive Assets
- Accelerate Commercialization
- Grow the BioHealth Capital Region Cluster

Advancing Science. Accelerating Innovation.

BioHealthCapital.com

Our Goal: To become a Top 3 BioHealth Hub by 2023




A BIG THANK YOU TO









A Call To Action

" Somebody has to do something, and it's just incredibly pathetic that is has to be US."

> -- Jerry Garcia of the Grateful Dead

THIS US IS YOU!

